Hormone Therapy Tied to Less Biological Aging in Postmenopausal Women
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- Postmenopausal women who use hormone therapy (HT) are biologically younger than those not receiving HT, according to a study published online Aug. 29 in JAMA Network Open.
Yufan Liu and Chenglong Li, Ph.D., from Peking University in Beijing, evaluated the association between HT use and discrepancies between chronological and biological age in postmenopausal women, as well as the impact of socioeconomic status (SES). The analysis included data from 117,763 postmenopausal women participating in the U.K. Biobank, of whom 40.3 percent ever used HT.
The researchers found that ever use of HT was associated with a smaller biological aging discrepancy versus never use of HT (β, −0.17 years). This effect was more evident in those who started HT at 55 years of age or older (β, −0.32 years) and in those who used HT for four to eight years (β, −0.25 years). Additionally, the association between HT and a smaller aging discrepancy was stronger in women with low SES, with a significant interaction observed for education (higher education: β, −0.08 years; other education: β, −0.23). For the association between HT and all-cause mortality and cause-specific mortality, phenotypic aging discrepancy mediated 12.7 percent of the effect.
"Promoting HT in postmenopausal women could be important for healthy aging," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Nicotine, Marijuana Use Underreported by Plastic Surgery Patients
WEDNESDAY, Sept. 4, 2024 -- Plastic surgery patients who use marijuana also have elevated nicotine levels, according to a study published in the September issue of Plastic...
Menopausal Transition Linked to Adverse Changes in Lipoprotein Profile
FRIDAY, Aug. 30, 2024 -- Menopausal status is associated with adverse changes in lipoprotein profiles, according to a study presented at the European Society of Cardiology...
Elinzanetant Efficacious, Well-Tolerated for Vasomotor Symptoms
TUESDAY, Aug. 27, 2024 -- For menopausal vasomotor symptoms (VMS), elinzanetant is efficacious and well-tolerated, according to a study published online Aug. 22 in the Journal of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.